Predict your next investment

HEALTHCARE | Drug Development

See what CB Insights has to offer

Founded Year



Acquired | Acquired

Total Raised


About Onspira Therapeutics

Onspira Therapeutics is focused on the development of medicines for patients suffering from rare pulmonary diseases. Its lead program is an inhaled IL-1 (beta) antagonist protein being advanced for the treatment of bronchiolitis obliterans syndrome (BOS) in post-lung transplant patients.On January 8, 2020, Onspira Therapeutics was acquired by Altavant Sciences. The terms of the transaction were not disclosed.

Onspira Therapeutics Headquarter Location

640 Lee Road Suite 117

Wayne, Pennsylvania, 19087,

United States


Latest Onspira Therapeutics News

Altavant Sciences’ Acquisition Of Onspira Therapeutics

Jan 10, 2020

Hogan Lovells advised Altavant Sciences in its acquisition of Onspira Therapeutics. This acquisition expanded Altavant’s pipeline to include OSP-101, a novel inhaled interleukin-1 receptor antagonist (IL-1Ra) with US FDA orphan drug designation. OSP-101 is in development for the treatment of bronchiolitis obliterans syndrome (BOS), the leading cause of morbidity and mortality in post-lung transplant patients. Onspira Therapeutics is a private drug development company similarly focused on therapeutics for rare pulmonary diseases. Altavant Sciences is a clinical-stage biopharmaceutical company formed to advance promising therapies that treat rare respiratory diseases with an initial therapeutic focus in pulmonary arterial hypertension.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Onspira Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Onspira Therapeutics is included in 1 Expert Collection, including Biopharmaceuticals.



5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.